US OptionsDetailed Quotes

MRK241220C115000

Watchlist

0.01
0.000.00%

15min DelayTrading Dec 17 10:28 ET

0.01High0.01Low

Merck & Co Stock Discussion

Stock_Drift

4 hours ago

$Merck & Co (MRK.US)$

Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season

10xStockPicks

Dec 15 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

10xStockPicks

Dec 14 21:19

This $2.25 Stock Soon To Turn A Profit Is Highly Likely To Be Acquired Above $10

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...

Mr Long Term

Dec 12 18:17

Columns These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over.

It's been a banner year for the stock market. However, not every stock has been a winner as some sectors performed better than others. Tech and utilities soared, while others like real estate and healthcare underperformed.
So what are the five worst performers on the Dow Jones Industrial Average list of blue chip stocks? Let's take a look.
1. Boeing (down 36.5%)
Boeing $Boeing (BA.US)$ has had a r...

Cow Moo-ney

Dec 12 09:38

Slightly hotter PPI

One day after we got an inflation data (CPI) that came in line with expectation, the market received a hotter-than-expected producer price index (PPI) reading for November.
This is probably why the market is retreating a little bit.
That said, I believe the Fed will still proceed with its expected 25 basis point rate cut next week because other inflation data over the past few months are showing that it is trending downwards.
$Vanguard S&P 500 ETF (VOO.US)$ $KraneShares CSI China Internet ETF (KWEB.US)$ $First Republic Bank (FRCB.US)$ $Crude Oil Futures(FEB5) (CLmain.US)$ $Goldman Sachs (GS.US)$ $Citigroup (C.US)$ $ChargePoint (CHPT.US)$ $LivePerson (LPSN.US)$ $Clover Health (CLOV.US)$ $Vanguard Growth ETF (VUG.US)$ $JD.com (JD.US)$ $Baidu (BIDU.US)$ $FuboTV (FUBO.US)$ $Merck & Co (MRK.US)$ $The Trade Desk (TTD.US)$

https://youtu.be/XKCRqd1-5go

From YouTube

Fed's year-end meeting: How it will reveal market trends!

籠的傳人288

Dec 10 03:30

Rolling sell put csp contracts for mrk.

Alot of times you would hear people say, roll down (csp) or roll up (covered call) their option contracts. Basically rolling your contract is cancel the first contract (cut loss) and open a new second contract. But the second contract must cover the loss of the first contract or minimum must break even or take a small loss.
On oct 10/24, open 2 x mrk contracts at 109.29c, strike at 105 and premium of 192 x 2 (35 dte). On nov 5/24, i closed 2 x contracts a...

This_Guy

Dec 8 17:14

$Merck & Co (MRK.US)$
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Positive
100% complete response rate achieved at 1.75 mg/kg dose level
High overall response rate across all dosage groups (93.3-100%)
Strong 12-month duration of response at 93.5%
Successfully established recommended Phase 3 dose
Negative
58% of patients exp...

Stock_Drift

Dec 8 15:26

$Merck & Co (MRK.US)$

Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

Bellaah

Dec 5 13:16

$Merck & Co (MRK.US)$ 110

No comment yet